Sunitinib added to FOLFIRI versus FOLFIRI in patients with chemorefractory advanced adenocarcinoma of the stomach or lower esophagus: a randomized, placebo-controlled phase II AIO trial with serum biomarker program.

BMC Cancer · 2016 · PMC5006426 · PMID 27582078

Europe PMC DOI

hedged sentences

0.0580

closest p · 1.2× alpha

0.0580

boldest claim

The sentences

a strong trendP = 0.058so close (0.05 < p ≤ 0.1)

Additionally, a strong trend to a longer OS of 11.07 months ± 63 days for the group with low VEGF-A baseline levels versus 7.56 months ± 73 days (HR 0.602, 95 % CI 0.356–1.018, P = 0.058) was detected. sVEGFR2 The median concentration of sVEGFR2 prior to the start of study treatment was 4688 pg/ml for 65 evaluable patients.

also in 5,725 other papers

showed a trendno p-value reported

The OS showed a trend in favor of SUN compared with PL, 315 vs. 270 days (10.4 vs. 8.9 months).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.